JP2015519359A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015519359A5 JP2015519359A5 JP2015514666A JP2015514666A JP2015519359A5 JP 2015519359 A5 JP2015519359 A5 JP 2015519359A5 JP 2015514666 A JP2015514666 A JP 2015514666A JP 2015514666 A JP2015514666 A JP 2015514666A JP 2015519359 A5 JP2015519359 A5 JP 2015519359A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- group
- immunogenic compound
- peptide
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 230000002163 immunogen Effects 0.000 claims 10
- 235000001014 amino acid Nutrition 0.000 claims 9
- 229940024606 amino acid Drugs 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 229960005486 vaccine Drugs 0.000 claims 6
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims 5
- 125000005647 linker group Chemical group 0.000 claims 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- 235000004279 alanine Nutrition 0.000 claims 3
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 3
- 239000001488 sodium phosphate Substances 0.000 claims 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 3
- PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 2
- 102000014914 Carrier Proteins Human genes 0.000 claims 2
- 108010078791 Carrier Proteins Proteins 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 235000009582 asparagine Nutrition 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 230000001571 immunoadjuvant effect Effects 0.000 claims 2
- 239000000568 immunological adjuvant Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 1
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305602.0 | 2012-05-31 | ||
| EP12305602.0A EP2668959B1 (en) | 2012-05-31 | 2012-05-31 | Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein |
| PCT/IB2013/054482 WO2013179262A1 (en) | 2012-05-31 | 2013-05-30 | Immunogenic compounds comprising hiv gp41 peptide coupled to crm197 carrier protein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015519359A JP2015519359A (ja) | 2015-07-09 |
| JP2015519359A5 true JP2015519359A5 (enExample) | 2016-06-23 |
| JP6352251B2 JP6352251B2 (ja) | 2018-07-04 |
Family
ID=48793339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514666A Active JP6352251B2 (ja) | 2012-05-31 | 2013-05-30 | Ｃｒｍ１９７担体タンパク質に結合したｈｉｖｇｐ４１ペプチドを含む免疫原性化合物 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9511136B2 (enExample) |
| EP (2) | EP2668959B1 (enExample) |
| JP (1) | JP6352251B2 (enExample) |
| KR (1) | KR102077876B1 (enExample) |
| CN (1) | CN104507496B (enExample) |
| AU (1) | AU2013269120B2 (enExample) |
| BR (1) | BR112014029861B1 (enExample) |
| CA (1) | CA2875162C (enExample) |
| DK (1) | DK2668959T3 (enExample) |
| EA (1) | EA027803B1 (enExample) |
| ES (2) | ES2528109T3 (enExample) |
| HR (1) | HRP20150058T1 (enExample) |
| IN (1) | IN2014DN10128A (enExample) |
| MX (1) | MX360206B (enExample) |
| PL (1) | PL2668959T3 (enExample) |
| PT (1) | PT2668959E (enExample) |
| RS (1) | RS53769B1 (enExample) |
| SI (1) | SI2668959T1 (enExample) |
| UA (1) | UA118542C2 (enExample) |
| WO (1) | WO2013179262A1 (enExample) |
| ZA (1) | ZA201409023B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140335119A1 (en) * | 2004-02-06 | 2014-11-13 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL |
| US10532090B2 (en) * | 2015-04-17 | 2020-01-14 | Biolife Science Qld Limited | Vaccine composition and uses thereof |
| WO2016184973A1 (en) * | 2015-05-19 | 2016-11-24 | Innavirvax | Treatment of hiv-infected individuals |
| WO2016184963A1 (en) | 2015-05-19 | 2016-11-24 | Innavirvax | Treatment of hiv-infected individuals |
| WO2016184962A1 (en) | 2015-05-19 | 2016-11-24 | Innavirvax | Treatment of hiv-infected individuals |
| EP3574915A1 (en) * | 2018-05-29 | 2019-12-04 | Neovacs | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity |
| EP4115900A1 (en) * | 2021-07-05 | 2023-01-11 | Diaccurate | Novel antigens and vaccines |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1445614A1 (en) * | 2003-02-06 | 2004-08-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | A method for the in vitro assessment of the progression status of an HIV virus in an invidual |
| EP2460813A1 (en) * | 2003-12-17 | 2012-06-06 | Janssen Alzheimer Immunotherapy | A beta immunogenic peptide carrier conjugates and methods of producing same |
| CA2735278A1 (en) * | 2008-08-28 | 2010-03-04 | Aarhus Universitet | Hiv-1 envelope polypeptides for hiv vaccine |
| US7965010B2 (en) * | 2008-09-03 | 2011-06-21 | Bose Corporation | Linear motor with patterned magnet arrays |
| WO2010040853A1 (en) * | 2008-10-10 | 2010-04-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A method for the screening of candidate substances active against the infection of a subject by a hiv virus and kits for performing the said method |
-
2012
- 2012-05-31 RS RS20150035A patent/RS53769B1/sr unknown
- 2012-05-31 PT PT123056020T patent/PT2668959E/pt unknown
- 2012-05-31 PL PL12305602T patent/PL2668959T3/pl unknown
- 2012-05-31 ES ES12305602.0T patent/ES2528109T3/es active Active
- 2012-05-31 SI SI201230130T patent/SI2668959T1/sl unknown
- 2012-05-31 DK DK12305602.0T patent/DK2668959T3/en active
- 2012-05-31 EP EP12305602.0A patent/EP2668959B1/en active Active
-
2013
- 2013-05-30 IN IN10128DEN2014 patent/IN2014DN10128A/en unknown
- 2013-05-30 AU AU2013269120A patent/AU2013269120B2/en active Active
- 2013-05-30 EA EA201491969A patent/EA027803B1/ru not_active IP Right Cessation
- 2013-05-30 WO PCT/IB2013/054482 patent/WO2013179262A1/en not_active Ceased
- 2013-05-30 UA UAA201412809A patent/UA118542C2/uk unknown
- 2013-05-30 BR BR112014029861-0A patent/BR112014029861B1/pt active IP Right Grant
- 2013-05-30 MX MX2014014526A patent/MX360206B/es active IP Right Grant
- 2013-05-30 EP EP13737420.3A patent/EP2854846B1/en active Active
- 2013-05-30 CN CN201380041048.0A patent/CN104507496B/zh active Active
- 2013-05-30 CA CA2875162A patent/CA2875162C/en active Active
- 2013-05-30 KR KR1020147036531A patent/KR102077876B1/ko active Active
- 2013-05-30 JP JP2015514666A patent/JP6352251B2/ja active Active
- 2013-05-30 US US14/404,254 patent/US9511136B2/en active Active
- 2013-05-30 ES ES13737420T patent/ES2701084T3/es active Active
-
2014
- 2014-12-09 ZA ZA2014/09023A patent/ZA201409023B/en unknown
-
2015
- 2015-01-16 HR HRP20150058AT patent/HRP20150058T1/hr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015519359A5 (enExample) | ||
| IL308807B2 (en) | Combination therapy for treating cancer | |
| PH12021551116A1 (en) | Functionalized heterocycles as antiviral agents | |
| RU2008126305A (ru) | Новый пептид | |
| JP6294868B2 (ja) | 液体水性組成物 | |
| JP2016522159A5 (enExample) | ||
| HRP20150058T1 (hr) | Imunogeni spojevi koji sadrže hiv gp41 peptid vezan na protein nosaäś crm197 | |
| RU2012140704A (ru) | Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция | |
| JP2014508734A5 (enExample) | ||
| MX2021003253A (es) | Heterociclos funcionalizados como agentes antivirales. | |
| JP2010536714A5 (enExample) | ||
| JP2015500827A5 (enExample) | ||
| EP2618842A1 (en) | Novel immunostimulatory method | |
| JP2019509280A5 (enExample) | ||
| WO2021055425A3 (en) | Functionalized heterocycles as antiviral agents | |
| MX2011007963A (es) | Peptidos neil3 y vacunas que incluyen los mismos. | |
| JP2014527526A5 (enExample) | ||
| JP2014525939A5 (enExample) | ||
| RU2014111179A (ru) | КОНЪЮГАТЫ ИНТЕРФЕРОНА λ1 И ПОЛИЭТИЛЕНГЛИКОЛЯ | |
| TWI635095B (zh) | 衍生自精胺酸密集區之經修飾抗菌胜肽 | |
| JP2020515283A5 (enExample) | ||
| JP2019534242A5 (enExample) | ||
| JP2012515752A (ja) | 安定なワクチン組成物とその使用方法 | |
| JP2013542196A5 (enExample) | ||
| JP2016518321A5 (enExample) |